|
0021.0001 CG 425 METAVIVOR
|
261200800001E
|
$319,219,481
|
UNKNOWN, UNKNOWN
|
LEIDOS BIOMEDICAL RESEARCH, INC.
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cancer and Other Mortality Risks in a Cohort of U.S. Radiologic Technologists
|
ZIA CP010133-04180
|
$390,015
|
Linet, Martha
|
DCEG (NCI)
|
|
Cancer Center Support Grant
|
3P30CA082103-18S9
|
$6,765,398
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18SA
|
$124,999
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18SB
|
$59,999
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA042014-28S1
|
$249,799
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S2
|
$123,315
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S3
|
$46,117
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S4
|
$59,999
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S5
|
$113,563
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S6
|
$75,709
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S7
|
$75,000
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S8
|
$166,146
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
5P30CA042014-28
|
$2,284,983
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA091842-16S1
|
$122,824
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA091842-16S2
|
$243,947
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
5P30CA091842-16
|
$4,305,712
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-08S1
|
$175,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-08
|
$2,480,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Risk in Myotonic Dystrophy
|
ZIA CP010144-10568
|
$94,531
|
Gadalla, Shahinaz
|
DCEG (NCI)
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S1
|
$118,875
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S2
|
$60,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S3
|
$200,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S4
|
$145,821
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-27
|
$4,895,515
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Cataract after low dose and low dose rate exposure
|
ZIA CP010133-10717
|
$6,786
|
Little, Mark
|
DCEG (NCI)
|
|
Clinical Studies of the Molecular Genetic Basis of Kidney Cancer
|
ZIA BC 011028
|
$511,064
|
Linehan, W. Marston
|
CCR (NCI)
|
|
Collecting multiple primary tumor tissues
|
ZIA CP010131-10719
|
$30,688
|
Morton, Lindsay
|
DCEG (NCI)
|
|
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA
|
5R01CA214146-02
|
$348,844
|
GUTMANN, DAVID
|
WASHINGTON UNIVERSITY
|
|
DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural
|
ZIA CP010144-10548
|
$1,414,523
|
Stewart, Douglas
|
DCEG (NCI)
|
|
DNA Repair in Human Cancer-Prone Genetic Diseases
|
ZIA BC 004517
|
$1,059,524
|
Kraemer, Kenneth
|
CCR (NCI)
|
|
Families at high risk of cancer
|
ZIA CP004410-08285
|
$246,303
|
Caporaso, Neil
|
DCEG (NCI)
|
|
Flow Cytometric Detection of Malignant Cells in Body Fluids
|
ZIC BC 011093
|
$168,285
|
Stetler-Stevenson, Maryalice
|
CCR (NCI)
|
|
Genome-edited uveal melanoma cell lines for investigating constitutively active GNAQ and GNA11
|
5R03CA202316-02
|
$78,000
|
WEDEGAERTNER, PHILIP
|
THOMAS JEFFERSON UNIVERSITY
|
|
Genomics of multiple primary tumors
|
ZIA CP010131-10782
|
$214,814
|
Morton, Lindsay
|
DCEG (NCI)
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-04
|
$701,778
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Identifying a nodal point for G alpha q signaling in eye disease
|
5R01CA202778-02
|
$340,838
|
ODELBERG, SHANNON
|
UNIVERSITY OF UTAH
|
|
IMMUNOLOGICAL MODULATION OF OCULAR TUMOR METASTASES
|
5R01CA030276-35
|
$282,171
|
NIEDERKORN, JERRY
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Immunotherapy Strategies for Uveal Melanoma
|
ZIA BC 010649
|
$294,260
|
Kammula, Udai
|
CCR (NCI)
|
|
Improving the Clinical Effectiveness and Understanding of the Biophysical Basis
|
5U19CA021239-38
|
$2,457,927
|
HONG, THEODORE
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Mechanisms of Action for KCN1 in the Control of Uveal Melanoma Metastasis
|
5R01CA176001-04
|
$323,700
|
GROSSNIKLAUS, HANS
|
EMORY UNIVERSITY
|
|
Mechanisms of Cross-talk Between EphrinB and Alternate Signaling Pathways
|
ZIA BC 010006
|
$427,953
|
Daar, Ira
|
CCR (NCI)
|
|
Molecular Genetics of Melanoma
|
5K24CA149202-08
|
$171,081
|
TSAO, HENSIN
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Molecular Mechanism and Therapy for Ocular Melanoma
|
1R01CA217642-01
|
$488,005
|
ZHANG, KANG
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Molecular Predictive Testing in Ocular Melanoma
|
2R01CA125970-11
|
$561,808
|
HARBOUR, JAMES
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|